Search - tctmd.com

Displaying 101 - 120 of 251

Sort: Relevancy | Date

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

News Conference News PCR London Valves 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

September 27, 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

June 19, 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

June 16, 2017

Subclinical Leaflet Thrombosis in Surgical and Transcatheter Bioprosthetic Aortic Valves – Cautionary Findings and Clinical Implications

Presentation TVT 2017

Subclinical Leaflet Thrombosis in Surgical and Transcatheter Bioprosthetic Aortic Valves Cautionary Findings and Clinical Implications

Presenter: Martin B. Leon, Hendrik Treede, Raj Makkar

June 16, 2017

Management of Acute Coronary Syndromes and Left Main CAD in AS Patients: Case Examples and Procedural Techniques

Presentation TVT 2017

Management of Acute Coronary Syndromes and Left Main CAD in AS Patients: Case Examples and Procedural Techniques

Presenter: Raj Makkar

June 16, 2017

The Portico TAVR System: A “Cool” Case, New Technology, and Clinical Program Updates

Presentation TVT 2017

The Portico TAVR System: A Cool Case, New Technology, and Clinical Program Updates

Presenter: Martin B. Leon, Michael J. Reardon, Raj Makkar

June 16, 2017

A Critical Appraisal of REPRISE III

Presentation TVT 2017

A Critical Appraisal of REPRISE III

Presenter: Axel Linke, Jeffrey J. Popma, Raj Makkar

June 15, 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

May 17, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Daily News

TAVR 球囊膨胀后的小叶增厚、球囊耐久性：研究提供新见解

December 26, 2016

News Daily News

Leaflet Thickening, Valve Durability After Balloon-Expandable TAVR: Studies Offer New Insights

December 26, 2016

News Daily News

Engrosamiento de las Valvas y Durabilidad de la Válvula Post-TAVR con Balón Autoexpandible: Nuevos Datos de Estudios

December 26, 2016

Valve Degeneration and Mobility Considerations: Assessing Clinical Relevance

Presentation TCT 2016

Valve Degeneration and Mobility Considerations: Assessing Clinical Relevance

Presenter: Nicole Ibrahim, Martin B. Leon, Raj Makkar

November 01, 2016

News Conference News TCT 2016

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

November 01, 2016

Portico: Design Features, Special Attributes, and Clinical Trial Program

Presentation TCT 2016

Portico: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Raj Makkar

November 01, 2016

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

November 01, 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presentation TCT 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno

October 31, 2016

Controversy 5. Adjunctive Pharmacotherapy for TAVR: “Real World” Usage Patterns of Antiplatelet and Antithrombotic Agents

Presentation TCT 2016

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Presenter: Raj Makkar, Lars Sondergaard, Luis Nombela-Franco

October 31, 2016

Flash Debate: Counterpoint – In Lower Risk Patients, A Thoughtful “Hybrid” Strategy Is Preferred!

Presentation TCT 2016

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker

October 31, 2016

Flash Debate: Point – In Lower Risk Patients, the Minimalist Strategy Should Be the “Default” Approach!

Presentation TCT 2016

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo

October 31, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.